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Chlamydia pneumoniae IgG
seropositivity and risk of deep-vein
thrombosis
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J D Emmerich, J T van Dissel
In a population-based case-control study of 474 patients with a
first episode of deep-vein thrombosis and 474 age-matched and
sex-matched controls, we found no effect of Chlamydia
pneumoniae Infection on the occurrence of deep-vein thrombosis.
Deep-vein thrombosis is a common disease with an annual
incidence in the general population of about l per 1000.
Numerous acquired and inherited risk factors have been
identified, but many thrombotic episodes occur in the
absence of these predisposing conditions. High titres of IgG
antibodies against Chlamydia pneumoniae have been
associated' with an overall increased risk of venous
thromboembolism of between six-fold and seven-fold;1 in
that study, patients with the highest IgG titres (3= 1:1024 in
14% of all patients) had the most pronounced risk· (odds
ratio 32). Chronic chlamydia infections may lead to
increased concentrations of clotting-factor VIII, which is also
a strong risk factor for venous thrombosis.2 However, the
' mechanisrn by which high concentrations of this clotting
facior Icads to thrombosis is still unknown. Research also
suggests that markers of inflammation, such äs C-reactive
protein, are increased in patients with venous thrombosis.3
We compared IgG titres against C pneumoniae among 474
unselected outpatients with a first, objectively confirmed
episode of deep-vein thrombosis and 474 age-matched and
sex-matched healthy controls. We also looked for a possible
relation between IgG titres and concentrations of clotting-
factor Vni and other markers of the acute-phase reaction.
The selection procedures for patients and controls have
been described in detail previously.4 Briefly, we included 474
consecutive outpatients, younger than 70 years of age, who
were referred for monitoring of anticoagulant treatment after
a first, objectively confimed episode of deep-vein thrombosis
that occurred between Jan l, 1988, and Dec 31, 1992.
Patients with a known malignant disease were excluded. 90%

























»Reference category; adjustment for levei of education, and concentration of fibrinogen
clottmg-factor VIII, and C-reactive protein did not alter the results.
Thrombosis risk for several concentrations of IgG against
C pneumon/ae
each patient, we enrolled one healthy age-matched and sex-
matched control (53% were friends, 47% were partners of
other patients). The controls and cases were inhabitants of
the sarne geographical area and had on average the same level
of education. The median time between the occurrence of
deep-vein thrombosis and venepuncture for this study was
19 months (ränge 6-68). C pneumoniae serological Status wa^
measured with a qualitative ELJSA (Savyon SeroCP-IgG kit.
Ashdod, Israel). A test was regarded äs positive when the cui-
off index was greater than l · l. Technicians were unaware of
whether samples were from patients or controls. V!'e
calculated odds ratios with 95% CIs äs estimates of the
relative risk by simple cross tabulation. Since concentrations
of IgG against C pneumoniae have a continuum of values
instead of binary outcomes, we also calculated odds rauos
over several strata of antibody responses.
The mean age of patients and controls was 45 years (ränge
15-69 for patients, 15-72 for controls). 57% of patients and
controls were women. Positive C pneumoniae serology wa^
detected in 380 (80%) of the 474 patients, and 371 (78%) of
controls (odds ratio 1-1 [95% CI 0-9-1-4]). The high
prevalence of exposure to C pneumoniae is in agreement with
the reported prevalences in other published reports.5 The
table presents the thrombosis risk for several categories of
IgG responses against C pneumoniae. Patients and controls
were equally distributed over the strata of IgG
concentrations. Among patients and controls there was a
poor correlation between concentrations of IgG againsi
chlamydia and concentrations of factor VIII: C, C-reacove
protein, and fibrinogen (Pearson's correlation coefficients
-0-07, -0-07, and 0-04, respectively).
The finding of a similarly high prevalence of IgG
seropositivity to C pneumoniae in 474 outpatients with a fest,
objectively diagnosed episode of venous thrombosis, and in
474 healthy age-matched and sex-matched controls suggests
that IgG seropositivity to C pneumoniae is not associated with
an increased risk of deep-vein thrombosis, and thus that
prior C pneumoniae infection does not increase the risk of
venous thrombosis. We also found no evidence of an
association between IgG seropositivity and clotting factor
Vin and other markers of the acute-phase reaction.
Our Undings are in contrast with those reported by
Lozinguez and colleagues,1.. who found that significantlii
more patients than controls had high IgG titres (5=1:256)
against C pneumoniae (54% vs 16%). We suggest that the
Undings of Lozinguez and colleagues may have been biased
by the probable higher socioeconomic Status of the controls!
who were recruited from a health-care centre to which they
had been referred for a routine check-up. The role of pnor
infection with C pneumoniae in the occurrence of deep-vein
thrombosis remains a disputed issue.
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